Cargando…

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine

Detalles Bibliográficos
Autores principales:	Pons-Tostivint, Elvire, Bennouna, Jaafar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600125/ https://www.ncbi.nlm.nih.gov/pubmed/36290835 http://dx.doi.org/10.3390/curroncol29100558

Ejemplares similares

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature
por: Mathiot, Laurent, et al.
Publicado: (2022)

Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma
por: Pons-Tostivint, Elvire
Publicado: (2023)

Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
por: Denis, Marc G., et al.
Publicado: (2023)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

A fatal case associated with Catabacter hongkongensis bacteremia in lung cancer patient: A case report
por: Mandin, Valentin, et al.
Publicado: (2022)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019)

Knowing the Bad: Adverse Event–Informed, High-Risk, Early-Stage Non-Small Cell Lung Cancer Treatment Options
por: Phillips, Joseph D.
Publicado: (2022)

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
por: Sundar, Raghav, et al.
Publicado: (2017)

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Precision medicine revolutionizes cancer diagnosis and treatment
por: Han, Chuanhui, et al.
Publicado: (2023)

Molecular biology tools for precision medicine in managing lung cancer
por: Mahesh, PA
Publicado: (2018)

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer
por: Ghiringhelli, Francois, et al.
Publicado: (2018)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
por: Villaruz, Liza C., et al.
Publicado: (2023)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

Understanding the Precision in “Precision Medicine”
por: Chabner, Bruce A.
Publicado: (2016)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer
por: Neal, Joel W.
Publicado: (2010)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Treatment time interval in breast cancer: A population‐based study on the impact of type and number of cancer centres attended
por: Martinez, Amalia, et al.
Publicado: (2022)

Precision Medicine
por: Pinho, João Renato Rebello
Publicado: (2017)

Precision medicine()
por: Nakanishi, Marcio
Publicado: (2018)

Precision Medicine for Personalized Cancer Therapy
por: Wong, Ada Hang-Heng, et al.
Publicado: (2015)

Delivering on the promise of precision cancer medicine
por: Berger, Michael F., et al.
Publicado: (2016)

Towards precision medicine in thyroid cancer
por: Xiao, Haipeng, et al.
Publicado: (2020)

Cancer Evolution in Precision Medicine Era
por: Karagiannis, Dimitris, et al.
Publicado: (2022)

Emerging Options for the Management of Non-Small Cell Lung Cancer
por: Binder, Daniel, et al.
Publicado: (2013)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
por: Yap, Timothy A, et al.
Publicado: (2014)

Precision radiotherapy for non-small cell lung cancer
por: Yang, Wen-Chi, et al.
Publicado: (2020)

From expert recommendations to multidisciplinary team decisions: a way to set out the novel perioperative options for patients with non-small-cell lung cancer
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
por: Diebels, Ian, et al.
Publicado: (2022)

Precision oncology- the future of personalized cancer medicine?
por: Bode, Ann M., et al.
Publicado: (2017)

Precision Medicine for Endocrinology
por: Azizi, Fereidoun
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gngkf4q2q5e6ghupt6f5itacpv